158 related articles for article (PubMed ID: 38388902)
1. 5-Methoxytryptophan enhances the sensitivity of sorafenib on the inhibition of proliferation and metastasis for lung cancer cells.
Chen HC; Kuo CY; Chang Y; Tsai DL; Lee MH; Lee JY; Lee HM; Su YC
BMC Cancer; 2024 Feb; 24(1):248. PubMed ID: 38388902
[TBL] [Abstract][Full Text] [Related]
2. Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
Wang HL; Ma X; Guan XY; Song C; Li GB; Yu YM; Yang LL
Pharmacol Res; 2022 Mar; 177():106050. PubMed ID: 34973468
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cancer cell epithelial mesenchymal transition by normal fibroblasts via production of 5-methoxytryptophan.
Cheng HH; Chu LY; Chiang LY; Chen HL; Kuo CC; Wu KK
Oncotarget; 2016 May; 7(21):31243-56. PubMed ID: 27145282
[TBL] [Abstract][Full Text] [Related]
4. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
[TBL] [Abstract][Full Text] [Related]
5. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
6. Polyphyllin I attenuates the invasion and metastasis via downregulating GRP78 in drug-resistant hepatocellular carcinoma cells.
Du H; Wu H; Kang Q; Liao M; Qin M; Chen N; Huang H; Huang D; Wang P; Tong G
Aging (Albany NY); 2023 Nov; 15(21):12251-12263. PubMed ID: 37934581
[TBL] [Abstract][Full Text] [Related]
7. Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Siddharth S; Kuppusamy P; Wu Q; Nagalingam A; Saxena NK; Sharma D
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897659
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
10. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Chen C; Ju R; Shi J; Chen W; Sun F; Zhu L; Li J; Zhang D; Ye C; Guo L
J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Deng L; Ren Z; Jia Q; Wu W; Shen H; Wang Y
BMC Cancer; 2013 Jul; 13():363. PubMed ID: 23895220
[TBL] [Abstract][Full Text] [Related]
12. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
13. 5-methoxytryptophan induced apoptosis and PI3K/Akt/FoxO3a phosphorylation in colorectal cancer.
Zhao TL; Qi Y; Wang YF; Wang Y; Liang H; Pu YB
World J Gastroenterol; 2023 Dec; 29(47):6148-6160. PubMed ID: 38186686
[TBL] [Abstract][Full Text] [Related]
14. 5-Methoxytryptophan-dependent inhibition of oral squamous cell carcinoma metastasis.
Wang SH; Chang CW; Chou HC
Electrophoresis; 2015 Sep; 36(17):2027-34. PubMed ID: 26171676
[TBL] [Abstract][Full Text] [Related]
15. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
[TBL] [Abstract][Full Text] [Related]
16. [Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
Deng LF; Wang YH; Jia QA; Ren ZG; Shen HJ; Sun XJ; Li JH
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):845-9. PubMed ID: 24331695
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
[TBL] [Abstract][Full Text] [Related]
18. Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
Wehler TC; Hamdi S; Maderer A; Graf C; Gockel I; Schmidtmann I; Hainz M; Berger MR; Theobald M; Galle PR; Moehler M; Schimanski CC
Int J Colorectal Dis; 2013 Mar; 28(3):385-98. PubMed ID: 22983756
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
